114 related articles for article (PubMed ID: 18280694)
1. A short series of antidiabetic sulfonylureas exhibit multiple ligand PPARgamma-binding patterns.
Arrault A; Rocchi S; Picard F; Maurois P; Pirotte B; Vamecq J
Biomed Pharmacother; 2009 Jan; 63(1):56-62. PubMed ID: 18280694
[TBL] [Abstract][Full Text] [Related]
2. Design and synthesis of 6-methyl-2-oxo-1,2,3,4-tetrahydro-pyrimidine-5-carboxylic acid derivatives as PPARgamma activators.
Kumar R; Mittal A; Ramachandran U
Bioorg Med Chem Lett; 2007 Aug; 17(16):4613-8. PubMed ID: 17574414
[TBL] [Abstract][Full Text] [Related]
3. The dipeptide H-Trp-Glu-OH shows highly antagonistic activity against PPARgamma: bioassay with molecular modeling simulation.
Ye F; Zhang ZS; Luo HB; Shen JH; Chen KX; Shen X; Jiang HL
Chembiochem; 2006 Jan; 7(1):74-82. PubMed ID: 16317783
[TBL] [Abstract][Full Text] [Related]
4. Antidiabetic effect of novel benzenesulfonylureas as PPAR-γ agonists and their anticancer effect.
Kharbanda C; Alam MS; Hamid H; Javed K; Dhulap A; Bano S; Ali Y
Bioorg Med Chem Lett; 2015 Oct; 25(20):4601-5. PubMed ID: 26384286
[TBL] [Abstract][Full Text] [Related]
5. Synthesis of docosahexaenoic acid derivatives designed as novel PPARgamma agonists and antidiabetic agents.
Itoh T; Murota I; Yoshikai K; Yamada S; Yamamoto K
Bioorg Med Chem; 2006 Jan; 14(1):98-108. PubMed ID: 16198578
[TBL] [Abstract][Full Text] [Related]
6. Design and structural analysis of novel pharmacophores for potent and selective peroxisome proliferator-activated receptor gamma agonists.
Lin CH; Peng YH; Coumar MS; Chittimalla SK; Liao CC; Lyn PC; Huang CC; Lien TW; Lin WH; Hsu JT; Cheng JH; Chen X; Wu JS; Chao YS; Lee HJ; Juo CG; Wu SY; Hsieh HP
J Med Chem; 2009 Apr; 52(8):2618-22. PubMed ID: 19301897
[TBL] [Abstract][Full Text] [Related]
7. Sulfonylureas and glinides exhibit peroxisome proliferator-activated receptor gamma activity: a combined virtual screening and biological assay approach.
Scarsi M; Podvinec M; Roth A; Hug H; Kersten S; Albrecht H; Schwede T; Meyer UA; Rücker C
Mol Pharmacol; 2007 Feb; 71(2):398-406. PubMed ID: 17082235
[TBL] [Abstract][Full Text] [Related]
8. A novel selective peroxisome proliferator-activator receptor-gamma modulator-SPPARgammaM5 improves insulin sensitivity with diminished adverse cardiovascular effects.
Chang CH; McNamara LA; Wu MS; Muise ES; Tan Y; Wood HB; Meinke PT; Thompson JR; Doebber TW; Berger JP; McCann ME
Eur J Pharmacol; 2008 Apr; 584(1):192-201. PubMed ID: 18346728
[TBL] [Abstract][Full Text] [Related]
9. PAR-1622 is a selective peroxisome proliferator-activated receptor gamma partial activator with preserved antidiabetic efficacy and broader safety profile for fluid retention.
Kim MK; Chae YN; Kim HS; Choi SH; Son MH; Kim SH; Kim JK; Moon HS; Park SK; Shin YA; Kim JG; Lee CH; Lim JI; Shin CY
Arch Pharm Res; 2009 May; 32(5):721-7. PubMed ID: 19471887
[TBL] [Abstract][Full Text] [Related]
10. Design, development and evaluation of novel dual PPARδ/PPARγ agonists.
Gathiaka S; Nanayakkara G; Boncher T; Acevedo O; Wyble J; Patel S; Patel A; Shane ME; Bonkowski B; Wieczorek J; Rong Y; Huggins K; Smith F; Amin RH
Bioorg Med Chem Lett; 2013 Feb; 23(3):873-9. PubMed ID: 23273519
[TBL] [Abstract][Full Text] [Related]
11. New oral antidiabetic drugs. Synthesis and structure-activity relationships.
Francia E; Marin A; Verdejo F; Sanchez MS; Morell J
Boll Chim Farm; 1975 Jul; 114(7):379-92. PubMed ID: 1164447
[No Abstract] [Full Text] [Related]
12. Design, synthesis, and activity evaluation of GK/PPARγ dual-target-directed ligands as hypoglycemic agents.
Lu J; Lei L; Huan Y; Li Y; Zhang L; Shen Z; Hu W; Feng Z
ChemMedChem; 2014 May; 9(5):922-7. PubMed ID: 24737574
[TBL] [Abstract][Full Text] [Related]
13. Structural insight into PPARgamma activation through covalent modification with endogenous fatty acids.
Waku T; Shiraki T; Oyama T; Fujimoto Y; Maebara K; Kamiya N; Jingami H; Morikawa K
J Mol Biol; 2009 Jan; 385(1):188-99. PubMed ID: 18977231
[TBL] [Abstract][Full Text] [Related]
14. Structure-based de novo design, synthesis, and biological evaluation of the indole-based PPARgamma ligands (I).
Dong X; Zhang Z; Wen R; Shen J; Shen X; Jiang H
Bioorg Med Chem Lett; 2006 Nov; 16(22):5913-6. PubMed ID: 17010604
[TBL] [Abstract][Full Text] [Related]
15. Effects of rosiglitazone--peroxisome proliferators-activated receptor gamma (PPARgamma) agonist on cell viability of human pituitary adenomas in vitro.
Winczyk K; Kunert-Radek J; Gruszka A; Radek M; Ławnicka H; Pawlikowski M
Neuro Endocrinol Lett; 2009 Mar; 30(1):107-10. PubMed ID: 19300395
[TBL] [Abstract][Full Text] [Related]
16. Design, synthesis, molecular modeling and anti-hyperglycemic evaluation of phthalimide-sulfonylurea hybrids as PPARγ and SUR agonists.
El-Zahabi MA; Elbendary ER; Bamanie FH; Radwan MF; Ghareib SA; Eissa IH
Bioorg Chem; 2019 Oct; 91():103115. PubMed ID: 31310882
[TBL] [Abstract][Full Text] [Related]
17. Development of docking-based 3D-QSAR models for PPARgamma full agonists.
Guasch L; Sala E; Valls C; Mulero M; Pujadas G; Garcia-Vallvé S
J Mol Graph Model; 2012 Jun; 36():1-9. PubMed ID: 22503857
[TBL] [Abstract][Full Text] [Related]
18. Dissociation of antihyperglycaemic and adverse effects of partial perioxisome proliferator-activated receptor (PPAR-gamma) agonist balaglitazone.
Larsen PJ; Lykkegaard K; Larsen LK; Fleckner J; Sauerberg P; Wassermann K; Wulff EM
Eur J Pharmacol; 2008 Oct; 596(1-3):173-9. PubMed ID: 18761337
[TBL] [Abstract][Full Text] [Related]
19. [Synthesis of phenyloxyisobutyric acid derivatives and their antidiabetic activity in vitro].
Zeng QL; Wang HQ; Luo H; Gao XP; Liu ZR; Li BG; Wang FP; Zhao YF
Yao Xue Xue Bao; 2006 Feb; 41(2):108-14. PubMed ID: 16671538
[TBL] [Abstract][Full Text] [Related]
20. New PPARgamma ligands based on 2-hydroxy-1,4-naphthoquinone: computer-aided design, synthesis, and receptor-binding studies.
Sundriyal S; Viswanad B; Bharathy E; Ramarao P; Chakraborti AK; Bharatam PV
Bioorg Med Chem Lett; 2008 Jun; 18(11):3192-5. PubMed ID: 18482837
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
